Cargando…

Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation

PURPOSE: N-(4-[(18)F]Fluorobenzoyl)interleukin-2 ([(18)F]FB-IL2) specifically binds to interleukin-2 receptors (IL-2R) and thus may be used to detect inflammation processes using positron emission tomography (PET). We now validated whether [(18)F]FB-IL2 can be used to quantify activated human periph...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Gialleonardo, Valentina, Signore, Alberto, Willemsen, Antoon T. M., Sijbesma, Jurgen W. A., Dierckx, Rudi A. J. O., de Vries, Erik F. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458201/
https://www.ncbi.nlm.nih.gov/pubmed/22777334
http://dx.doi.org/10.1007/s00259-012-2176-y
_version_ 1782244637096804352
author Di Gialleonardo, Valentina
Signore, Alberto
Willemsen, Antoon T. M.
Sijbesma, Jurgen W. A.
Dierckx, Rudi A. J. O.
de Vries, Erik F. J.
author_facet Di Gialleonardo, Valentina
Signore, Alberto
Willemsen, Antoon T. M.
Sijbesma, Jurgen W. A.
Dierckx, Rudi A. J. O.
de Vries, Erik F. J.
author_sort Di Gialleonardo, Valentina
collection PubMed
description PURPOSE: N-(4-[(18)F]Fluorobenzoyl)interleukin-2 ([(18)F]FB-IL2) specifically binds to interleukin-2 receptors (IL-2R) and thus may be used to detect inflammation processes using positron emission tomography (PET). We now validated whether [(18)F]FB-IL2 can be used to quantify activated human peripheral blood mononuclear cells (hPBMC) in rats by pharmacokinetic modelling. METHODS: Eleven Wistar rats were subcutaneously inoculated in the shoulder with different amounts of phytohaemagglutinin (PHA) activated hPBMC 15 min before i.v. injection of [(18)F]FB-IL2. A 60-min dynamic PET scan was acquired and arterial blood sampling and metabolite analysis were performed. At the end of the scan, animals were terminated and the inflammatory lesion dissected. PET data were analysed using Logan and Patlak analysis as well as one-tissue and two-tissue compartment models. Model preferences according to the Akaike information criterion (AIC) and correlation between PET measurements and the number of CD25-positive cells were evaluated. RESULTS: A high correlation between ex vivo tracer uptake (standardized uptake value) in the xenograft and the number of inoculated CD25-positive cells was observed (R (2) = 0.90). Plasma time-activity curves showed a rapid washout of the radiopharmaceutical from blood, while the time-activity curves of the inflammatory lesions showed slower washout. Time-activity curves could be fitted well by the Logan analysis method, indicating that the binding between [(18)F]FB-IL2 and CD25 is reversible. AIC indicated that data could be modelled best by a two-tissue reversible compartment model. A high correlation was observed between the binding potential and the number of CD25-positive cells (R (2) = 0.876, p < 0.0001). Based on binding potential measured by PET, the limit of detection was about 160,000 CD25-positive cells per 200 μl lesion (95 % confidence). CONCLUSION: [(18)F]FB-IL2 kinetics in this animal model of inflammation could be best described by a reversible two-tissue compartment model. The [(18)F]FB-IL2 binding potential is a suitable measure for accurate quantification of lymphocytic infiltration in pathological conditions with PET. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-012-2176-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3458201
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-34582012013-07-15 Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation Di Gialleonardo, Valentina Signore, Alberto Willemsen, Antoon T. M. Sijbesma, Jurgen W. A. Dierckx, Rudi A. J. O. de Vries, Erik F. J. Eur J Nucl Med Mol Imaging Original Article PURPOSE: N-(4-[(18)F]Fluorobenzoyl)interleukin-2 ([(18)F]FB-IL2) specifically binds to interleukin-2 receptors (IL-2R) and thus may be used to detect inflammation processes using positron emission tomography (PET). We now validated whether [(18)F]FB-IL2 can be used to quantify activated human peripheral blood mononuclear cells (hPBMC) in rats by pharmacokinetic modelling. METHODS: Eleven Wistar rats were subcutaneously inoculated in the shoulder with different amounts of phytohaemagglutinin (PHA) activated hPBMC 15 min before i.v. injection of [(18)F]FB-IL2. A 60-min dynamic PET scan was acquired and arterial blood sampling and metabolite analysis were performed. At the end of the scan, animals were terminated and the inflammatory lesion dissected. PET data were analysed using Logan and Patlak analysis as well as one-tissue and two-tissue compartment models. Model preferences according to the Akaike information criterion (AIC) and correlation between PET measurements and the number of CD25-positive cells were evaluated. RESULTS: A high correlation between ex vivo tracer uptake (standardized uptake value) in the xenograft and the number of inoculated CD25-positive cells was observed (R (2) = 0.90). Plasma time-activity curves showed a rapid washout of the radiopharmaceutical from blood, while the time-activity curves of the inflammatory lesions showed slower washout. Time-activity curves could be fitted well by the Logan analysis method, indicating that the binding between [(18)F]FB-IL2 and CD25 is reversible. AIC indicated that data could be modelled best by a two-tissue reversible compartment model. A high correlation was observed between the binding potential and the number of CD25-positive cells (R (2) = 0.876, p < 0.0001). Based on binding potential measured by PET, the limit of detection was about 160,000 CD25-positive cells per 200 μl lesion (95 % confidence). CONCLUSION: [(18)F]FB-IL2 kinetics in this animal model of inflammation could be best described by a reversible two-tissue compartment model. The [(18)F]FB-IL2 binding potential is a suitable measure for accurate quantification of lymphocytic infiltration in pathological conditions with PET. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-012-2176-y) contains supplementary material, which is available to authorized users. Springer-Verlag 2012-07-10 2012 /pmc/articles/PMC3458201/ /pubmed/22777334 http://dx.doi.org/10.1007/s00259-012-2176-y Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Di Gialleonardo, Valentina
Signore, Alberto
Willemsen, Antoon T. M.
Sijbesma, Jurgen W. A.
Dierckx, Rudi A. J. O.
de Vries, Erik F. J.
Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation
title Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation
title_full Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation
title_fullStr Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation
title_full_unstemmed Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation
title_short Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation
title_sort pharmacokinetic modelling of n-(4-[(18)f]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458201/
https://www.ncbi.nlm.nih.gov/pubmed/22777334
http://dx.doi.org/10.1007/s00259-012-2176-y
work_keys_str_mv AT digialleonardovalentina pharmacokineticmodellingofn418ffluorobenzoylinterleukin2bindingtoactivatedlymphocytesinanxenograftmodelofinflammation
AT signorealberto pharmacokineticmodellingofn418ffluorobenzoylinterleukin2bindingtoactivatedlymphocytesinanxenograftmodelofinflammation
AT willemsenantoontm pharmacokineticmodellingofn418ffluorobenzoylinterleukin2bindingtoactivatedlymphocytesinanxenograftmodelofinflammation
AT sijbesmajurgenwa pharmacokineticmodellingofn418ffluorobenzoylinterleukin2bindingtoactivatedlymphocytesinanxenograftmodelofinflammation
AT dierckxrudiajo pharmacokineticmodellingofn418ffluorobenzoylinterleukin2bindingtoactivatedlymphocytesinanxenograftmodelofinflammation
AT devrieserikfj pharmacokineticmodellingofn418ffluorobenzoylinterleukin2bindingtoactivatedlymphocytesinanxenograftmodelofinflammation